Comparative Study of TIS Efficacy Across Different Targets
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: TIS-STN, TIS-GP.
- Who it may be relevant to
- Registry conditions: PARKINSON DIS. Basic parameters: from 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparative Efficacy of Temporal Interference Stimulation at Different Targets in Parkinson's Disease
Overview
This prospective, randomized, participant- and outcome-assessor-blinded, parallel-group exploratory trial will compare the target-dependent clinical, neuroimaging, and electrophysiological effects of temporal interference stimulation (TIS) targeting the subthalamic nucleus (STN) or globus pallidus internus (GPi) in patients with Parkinson's disease (PD). Eighteen participants with idiopathic PD will be randomly assigned in a 1:1 ratio to the STN-TIS or GPi-TIS group. Participants will receive one 20-minute TIS session daily for 7 consecutive days. Motor symptoms will be assessed using the MDS-UPDRS Part III immediately before and after each daily stimulation session. Resting-state functional magnetic resonance imaging (fMRI) and 64-channel electroencephalography (EEG) will be performed before the first stimulation session and immediately after completion of the 7-day intervention. The primary outcomes are: (1) change in MDS-UPDRS Part III score from Day 1 before stimulation to Day 7 after stimulation; and (2) changes in regional spontaneous brain activity and seed-based functional connectivity measured using resting-state fMRI. Secondary outcomes are: (1) daily immediate changes in MDS-UPDRS Part III scores and the proportion of participants achieving at least 30% improvement at Day 7; and (2) changes in resting-state 64-channel EEG relative bandpower. Safety and tolerability will be evaluated by monitoring adverse events and local skin reactions throughout the intervention. This study aims to provide preliminary evidence regarding target-dependent functional response patterns associated with STN- and GPi-targeted TIS in PD.
Interventions
- Device TIS-STN
TIS stimulation target is the subthalamic nucleus (STN) , with a current intensity of 2 mA, base frequency of 2000 Hz, frequency difference of 130 Hz, and stimulation duration of 20 minutes. - Device TIS-GP
TIS stimulation target is the globus pallidus (GP), with a current intensity of 2 mA, base frequency of 2000 Hz, frequency difference of 130 Hz, and stimulation duration of 20 minutes.
Primary outcome measures
- Changes in motor symptoms in PD patients [Time frame: Immediately before the first stimulation session on Day 1 and immediately after the final stimulation session on Day 7.]
- Changes From Baseline in Regional Spontaneous Brain Activity and Seed-Based Functional Connectivity After 7 Days of TIS [Time frame: Baseline before the first stimulation session and immediately after completion of the 7-day intervention.]
Secondary outcome measures (2)
- Immediate Changes in MDS-UPDRS Part III Scores and Clinical Response Rate During the 7-Day TIS Intervention [Time frame: Immediately before and immediately after each stimulation session on Days 1 through 7; response rate assessed from immediately before the first stimulation session on Day 1 to immediately after the final stimulation session on Day 7.]
- Change From Baseline in Resting-State 64-Channel EEG Relative Bandpower After 7 Days of TIS [Time frame: Baseline before the first stimulation session and immediately after completion of the 7-day intervention.]
Eligibility criteria
Inclusion criteria
- Adult males or females aged ≥40 years;
- Diagnosis of idiopathic Parkinson's disease according to the UK Brain Bank criteria, with age of onset ≥40 years;
- Previous or current treatment with dopamine replacement therapy (e.g., levodopa) with good response;
- Hoehn and Yahr (H\&Y) stage 1.5-2.5;
- Able to walk independently for at least 5 minutes without assistive devices;
- No severe freezing of gait (FOG);
- Disease duration ≥2 years since diagnosis, clinically stable, and able to comply with study assessments and interventions;
- Stable medication regimen for at least 4 weeks prior to the study;
- Signed informed consent form; subject or legal guardian is able to understand and willing to participate in this study.
Exclusion criteria
- Presence of other neurological disorders that may affect the study (e.g., ...);
- Mild cognitive impairment or above (MoCA ≤23);
- Orthopedic or other medical conditions that may affect gait or balance;
- Contraindications to MRI, such as claustrophobia;
- History of antipsychotic, antidepressant, or other medications that may affect dopamine levels;
- History of other severe psychiatric disorders;
- History of epilepsy, traumatic brain injury, or implanted metallic devices in the brain or heart (e.g., stimulators, pacemakers) or other contraindications;
- History of electroconvulsive therapy (ECT);
- Currently participating in other gait- or balance-related intervention training;
- Physician-diagnosed cardiovascular risk factors for exercise.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Zhongnan Hospital of Wuhan University — Wuhan
Identifiers
NCT: NCT07745673 · linyanlun2025267